basal insulin with glp 1 Adding a GLP-1 receptor agonist was not associated a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation GLP-1 Receptor Agonists: An Alternative

The rapid weight loss achieved with GLP-1 medications may affect nutrient absorption and overall nutritional status, potentially impacting the bodys ability to maintain healthy teeth and gums

10.1073/pnas.1218051109

The SURMOUNT trial program provides extensive data on what tirzepatide achieves without any additional weight loss medication: 5 mg dose: 15.0% average weight loss at 72 weeks 10 mg dose: 19.5% average weight loss at 72 weeks 15 mg dose: 20.9% average weight loss at 72 weeks At 15 mg, 56.1% of participants lost at least 20% of body weight At 15 mg, 38.7% of participants lost at least 25% of body weight These numbers are remarkable

Research on many peptide blends is still developing, so having an expert guide you is the best way to minimize risks

Ferrari, E

This leaves the thyroid vulnerable